探花合集 Biologics Announces Appointment of VP, Business Development & Licensing
Mr. Hambly joins 探花合集 Biologics after spending nine years at Seattle Genetics, where he most recently served as Director of Business Development and was responsible for leading out-licensing activities for the company鈥檚 Antibody Drug Conjugate (ADC) technology. During his tenure, he was responsible for negotiating multiple ADC license and collaboration agreements with cumulative up-front license fees of over $100M, and potential milestone payments of over $1B. Kevin was also instrumental in driving strategic collaborations and in-licensing efforts to expand Seattle Genetics鈥 technology platforms and product pipeline.
Mr. Hambly holds a B.S. in Biochemistry and Cellular and Molecular Biology from Western Washington University, and a Master of Bioscience (MBS) from the Keck Graduate Institute of Applied Life Sciences.
鈥淜evin is a seasoned business development professional who has driven multiple high value deals for one of the leaders in Antibody Drug Conjugation technology,鈥 commented Mike Riley, Vice President and General Manager of 探花合集 Biologics. He added 鈥淜evin will play a key role as we continue to build 探花合集 Biologics into a leading solutions provider, which will help enable the next generation of biologic therapies.鈥
探花合集鈥檚 proprietary SMARTag site-specific protein-modification and linker technologies were developed by Redwood Bioscience to enable the generation of homogenous bioconjugates (including ADCs and other protein conjugates) engineered to enhance potency, safety and stability. The SMARTag platform provides precise payload positioning, stable, site-specific conjugation and defined stoichiometry of drug鈥損rotein ratios. The control afforded by the technology enables identification of superior drugs from libraries of differentially designed conjugates. 探花合集 acquired Redwood Bioscience in 2014.
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About 探花合集
探花合集 is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health and animal health products. With over 90 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 探花合集 employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. 探花合集 is headquartered in Somerset, N.J. For more information, visit www.catalent.com